Selda Erensoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Selda Erensoy has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Aysin Zeytinoglu
Department of Medical Microbiology, Faculty of Medicine, İzmir Economy University, Izmir 35330, Turkey
4 shared publications - Meltem Işıkgöz Taşbakan
Department of Infectious Diseases and Clinical Microbiology, Ege University Faculty of Medicine, Izmir, Türkiye
4 shared publications - Rüçhan Sertöz
Department of Medical Microbiology, Faculty of Medicine, Ege University, Izmir 35100, Turkey
4 shared publications - Candan Çiçek
Department of Medical Microbiology, Faculty of Medicine, Ege University, Izmir 35100, Turkey
3 shared publications - Mehmet Soylu
Faculty of Medicine, Department of Microbiology, Ege University, Izmir, Turkey
3 shared publications - Deniz Gokengin
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, 35100 Izmir, Turkey
2 shared publications
Latest Publications
- 3 September 2026
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 65 (3) , 487-496
Madde kullanım bozukluğu olan bireylerde hepatit ve HIV seroprevalansı
Amaç: Madde kullanım bozukluğu (MKB), güvenli olmayan enjeksiyon uygulamaları, riskli davranışlar ve olumsuz yaşam koşulları nedeniyle özellikle viral hepatitler ve HIV gibi kan yoluyla bulaşan enfeksiyonlar açısından önemli bir risk faktörü olarak kabul edilmektedir. Bu çalışmada MKB tanılı bireylerde hepatit A virüsü (HAV), hepatit B virüsü (HBV), hepatit C virüsü (HCV) ve HIV seroprevalansının belirlenmesi ve bu popülasyondaki tarama uygulamalarının değerlendirilmesi amaçlanmıştır.Gereç ve Yöntem: Bu retrospektif çalışmada, 1 Haziran 1998–1 Temmuz 2025 tarihleri arasında üçüncü basamak bir sağlık kurumunda bulunan psikiyatri kliniğinde MKB tanısıyla ayaktan takip edilen hastaların tıbbi kayıtları incelenmiştir. Hastaların demografik özellikleri, madde kullanım özellikleri ile HAV, HBV, HCV ve HIV serolojik sonuçları hastane kayıtlarından elde edilmiştir. Seropozitiflik oranları hesaplanmış ve tarama uygulamaları değerlendirilmiştir.Bulgular: Çalışma döneminde toplam 8.145 hastaya ait kayıt incelenmiş, bunlardan en az bir serolojik test sonucu bulunan 2.478 hasta (%30,4) analize dahil edilmiştir. Hastaların medyan yaşı 33 yıl (ÇAA: 25–45) olup, %85,6’sı erkektir. Test edilen hastalar arasında anti-HAV IgG pozitifliği %63,6 olarak saptanmıştır. HBsAg pozitifliği %2,3, anti-HCV pozitifliği %1,9 ve HIV seropozitifliği %0,85 olarak bulunmuştur. Bununla birlikte hastaların önemli bir kısmında viral hepatitlere yönelik testlerin eksik olduğu ve kapsamlı taramanın yalnızca sınırlı sayıda hastada yapıldığı görülmüştür.Sonuç: MKB tanılı bireyler viral hepatitler ve HIV enfeksiyonu açısından risk altında olmaya devam etmektedir. Ancak bu popülasyonda tarama uygulamalarının yeterli düzeyde olmadığı görülmektedir. Bağımlılık poliklinikleri tarama, erken tanı ve tedaviye yönlendirme açısından önemli bir fırsat sunmaktadır. Standart tarama stratejilerinin uygulanması, bu enfeksiyonların saptanma oranlarını ve yönetimini iyileştirebilir.
- 3 September 2026
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 65 (3) , 487-496
Madde kullanım bozukluğu olan bireylerde hepatit ve HIV seroprevalansı
Amaç: Madde kullanım bozukluğu (MKB), güvenli olmayan enjeksiyon uygulamaları, riskli davranışlar ve olumsuz yaşam koşulları nedeniyle özellikle viral hepatitler ve HIV gibi kan yoluyla bulaşan enfeksiyonlar açısından önemli bir risk faktörü olarak kabul edilmektedir. Bu çalışmada MKB tanılı bireylerde hepatit A virüsü (HAV), hepatit B virüsü (HBV), hepatit C virüsü (HCV) ve HIV seroprevalansının belirlenmesi ve bu popülasyondaki tarama uygulamalarının değerlendirilmesi amaçlanmıştır.Gereç ve Yöntem: Bu retrospektif çalışmada, 1 Haziran 1998–1 Temmuz 2025 tarihleri arasında üçüncü basamak bir sağlık kurumunda bulunan psikiyatri kliniğinde MKB tanısıyla ayaktan takip edilen hastaların tıbbi kayıtları incelenmiştir. Hastaların demografik özellikleri, madde kullanım özellikleri ile HAV, HBV, HCV ve HIV serolojik sonuçları hastane kayıtlarından elde edilmiştir. Seropozitiflik oranları hesaplanmış ve tarama uygulamaları değerlendirilmiştir.Bulgular: Çalışma döneminde toplam 8.145 hastaya ait kayıt incelenmiş, bunlardan en az bir serolojik test sonucu bulunan 2.478 hasta (%30,4) analize dahil edilmiştir. Hastaların medyan yaşı 33 yıl (ÇAA: 25–45) olup, %85,6’sı erkektir. Test edilen hastalar arasında anti-HAV IgG pozitifliği %63,6 olarak saptanmıştır. HBsAg pozitifliği %2,3, anti-HCV pozitifliği %1,9 ve HIV seropozitifliği %0,85 olarak bulunmuştur. Bununla birlikte hastaların önemli bir kısmında viral hepatitlere yönelik testlerin eksik olduğu ve kapsamlı taramanın yalnızca sınırlı sayıda hastada yapıldığı görülmüştür.Sonuç: MKB tanılı bireyler viral hepatitler ve HIV enfeksiyonu açısından risk altında olmaya devam etmektedir. Ancak bu popülasyonda tarama uygulamalarının yeterli düzeyde olmadığı görülmektedir. Bağımlılık poliklinikleri tarama, erken tanı ve tedaviye yönlendirme açısından önemli bir fırsat sunmaktadır. Standart tarama stratejilerinin uygulanması, bu enfeksiyonların saptanma oranlarını ve yönetimini iyileştirebilir.
- 30 July 2026
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 60 (3) , 301-317
SARS-CoV-2’nin Yeni Nesil Dizileme Analizi ile Genomik Karakterizasyonu
- 30 July 2026
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 60 (3) , 301-317
SARS-CoV-2’nin Yeni Nesil Dizileme Analizi ile Genomik Karakterizasyonu
- Open Access
- 9 January 2026
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 34 (1) , 40-45
CMV prevention in heart transplant recipients: Comparative analysis of preemptive and prophylactic strategies
CMV prevention in heart transplant recipients: Comparative analysis of preemptive and prophylactic strategies - Turkish Journal of Thoracic and Cardiovascular Surgery
- 9 January 2026
- Published by Galenos Yayinevi in Turkish Journal of Thoracic and Cardiovascular Surgery
- Vol. 34 (1) , 40-45
Open AccessCMV prevention in heart transplant recipients: Comparative analysis of preemptive and prophylactic strategies
CMV prevention in heart transplant recipients: Comparative analysis of preemptive and prophylactic strategies - Turkish Journal of Thoracic and Cardiovascular Surgery
- Open Access
- 31 August 2025
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 19 (08) , 1159-1171
Evaluation of alternative clinical samples for the detection of SARS-CoV-2 and influenza virus by automated multiplex RT-PCR
Introduction: The aim of this study was to compare the performance of different clinical specimens—nasopharyngeal (NP) swabs collected by healthcare professionals (HCP-NP), self-collected nasal swabs (Sc-N), and saliva samples (S)—in diagnostic tests for investigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and influenza A/B RNA. Methodology: These clinical samples were collected from 404 symptomatic cases and tested with the SARS-CoV-2 and influenza A/B RNA tests on the cobas 6800 System of Roche Molecular Systems (Roche Molecular Systems, Pleasanton, USA). The SARS-CoV-2 or influenza virus infection status was determined for all patients based on the predefined criteria and corresponding algorithms. Positive and negative predictive values (PPV, NPV), sensitivity, specificity, coefficient of variation (CV), interrater reliability, correlation, ,and days of sample collection of these three sample types were analyzed. Results: There was almost perfect agreement between the these sample types for the diagnosis of SARS-CoV-2 and influenza A. The overall performance (PPV, NPV, sensitivity) and reproducibility (CV ≤ 6%) were favorable. Additionally, they showed similar trends for days of sample collection. Conclusions: Diagnostic detection of SARS-CoV-2 and influenza RNA from Sc-N and S samples was comparable to HCP-NP samples. Using these samples would provide an advantage in diagnosing SARS-CoV-2 and influenza A infection, as they can be easily collected without the need for viral transport media.
- 31 August 2025
- Published by Journal of Infection in Developing Countries in The Journal of Infection in Developing Countries
- Vol. 19 (08) , 1159-1171
Open AccessEvaluation of alternative clinical samples for the detection of SARS-CoV-2 and influenza virus by automated multiplex RT-PCR
Introduction: The aim of this study was to compare the performance of different clinical specimens—nasopharyngeal (NP) swabs collected by healthcare professionals (HCP-NP), self-collected nasal swabs (Sc-N), and saliva samples (S)—in diagnostic tests for investigating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA and influenza A/B RNA. Methodology: These clinical samples were collected from 404 symptomatic cases and tested with the SARS-CoV-2 and influenza A/B RNA tests on the cobas 6800 System of Roche Molecular Systems (Roche Molecular Systems, Pleasanton, USA). The SARS-CoV-2 or influenza virus infection status was determined for all patients based on the predefined criteria and corresponding algorithms. Positive and negative predictive values (PPV, NPV), sensitivity, specificity, coefficient of variation (CV), interrater reliability, correlation, ,and days of sample collection of these three sample types were analyzed. Results: There was almost perfect agreement between the these sample types for the diagnosis of SARS-CoV-2 and influenza A. The overall performance (PPV, NPV, sensitivity) and reproducibility (CV ≤ 6%) were favorable. Additionally, they showed similar trends for days of sample collection. Conclusions: Diagnostic detection of SARS-CoV-2 and influenza RNA from Sc-N and S samples was comparable to HCP-NP samples. Using these samples would provide an advantage in diagnosing SARS-CoV-2 and influenza A infection, as they can be easily collected without the need for viral transport media.
- Open Access
- 6 July 2025
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (3) , 433-439
Successful viral suppression in a two-year-old child with human immunodeficiency virus infection treated with bictegravir/emtricitabine/tenofovir alafenamide
Background. Adherence to antiretroviral therapy (ART) is a major challenge in pediatric human immunodeficiency virus (HIV) management, especially in young children due to medication formulation, administration difficulties, and psychosocial barriers. Single-tablet regimens (STRs) have been shown to improve adherence and viral suppression in adults and adolescents, yet their use in younger children remains limited. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is an STR with a high genetic barrier to resistance, making it a promising option for pediatric patients with adherence difficulties. Case Presentation. We report a case of a 2-year-old girl with perinatally acquired HIV who experienced persistent viremia despite multiple ART regimens. The mother received zidovudine prophylaxis during delivery, and the infant was started on zidovudine (AZT) prophylaxis on the first day of life. The patient’s ART history included AZT monotherapy at birth, followed by combination therapy with lamivudine (3TC), lopinavir/ritonavir (LPV/r), and later tenofovir/emtricitabine (TDF/FTC) with dolutegravir (DTG). Despite these regimens, poor adherence related to medication administration difficulties and caregiver challenges contributed to persistent viremia. A multidisciplinary team approach was implemented to address adherence barriers. Given the patient’s ongoing virological failure and resistance mutations (L76V and V179E), off-label use of BIC/FTC/TAF (50mg/200mg/25mg) was approved. The dosage was adjusted based on weight, and medication administration was closely monitored. Within one month of treatment, HIV RNA levels significantly declined from 1,800,000 to 207 copies/mL. Viral suppression was maintained over subsequent three-month intervals, with HIV RNA levels of 35, 40, and 43 copies/mL, alongside immune recovery as indicated by increased CD4 counts. Conclusion. The successful off-label use of BIC/FTC/TAF in a treatment-refractory pediatric HIV case highlights its potential efficacy in young patients facing adherence challenges. Its high genetic barrier to resistance and favorable tolerability make it a promising option when standard therapies fail. Further research is needed to optimize pediatric ART strategies and expand access to STRs globally.
- 6 July 2025
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 67 (3) , 433-439
Open AccessSuccessful viral suppression in a two-year-old child with human immunodeficiency virus infection treated with bictegravir/emtricitabine/tenofovir alafenamide
Background. Adherence to antiretroviral therapy (ART) is a major challenge in pediatric human immunodeficiency virus (HIV) management, especially in young children due to medication formulation, administration difficulties, and psychosocial barriers. Single-tablet regimens (STRs) have been shown to improve adherence and viral suppression in adults and adolescents, yet their use in younger children remains limited. Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is an STR with a high genetic barrier to resistance, making it a promising option for pediatric patients with adherence difficulties. Case Presentation. We report a case of a 2-year-old girl with perinatally acquired HIV who experienced persistent viremia despite multiple ART regimens. The mother received zidovudine prophylaxis during delivery, and the infant was started on zidovudine (AZT) prophylaxis on the first day of life. The patient’s ART history included AZT monotherapy at birth, followed by combination therapy with lamivudine (3TC), lopinavir/ritonavir (LPV/r), and later tenofovir/emtricitabine (TDF/FTC) with dolutegravir (DTG). Despite these regimens, poor adherence related to medication administration difficulties and caregiver challenges contributed to persistent viremia. A multidisciplinary team approach was implemented to address adherence barriers. Given the patient’s ongoing virological failure and resistance mutations (L76V and V179E), off-label use of BIC/FTC/TAF (50mg/200mg/25mg) was approved. The dosage was adjusted based on weight, and medication administration was closely monitored. Within one month of treatment, HIV RNA levels significantly declined from 1,800,000 to 207 copies/mL. Viral suppression was maintained over subsequent three-month intervals, with HIV RNA levels of 35, 40, and 43 copies/mL, alongside immune recovery as indicated by increased CD4 counts. Conclusion. The successful off-label use of BIC/FTC/TAF in a treatment-refractory pediatric HIV case highlights its potential efficacy in young patients facing adherence challenges. Its high genetic barrier to resistance and favorable tolerability make it a promising option when standard therapies fail. Further research is needed to optimize pediatric ART strategies and expand access to STRs globally.
- Open Access
COVID-19 Antibody Levels among Various Vaccination Groups, One-Year Antibody Follow-Up in Two University Hospitals from Western and Central Turkey
Various clinical outcomes, reinfections, vaccination programs, and antibody responses resulted from the COVID-19 pandemic. This study investigated the time-dependent changes in SARS-CoV-2 antibody responses in infected and/or vaccinated and unvaccinated individuals and to provide insights into spike and nucleocapsid antibodies, which fluctuate during infectious and non-infectious states. This cohort study was carried out at the Ege University Faculty of Medicine hospital in İzmir (western Turkey) and the Erciyes University Faculty of Medicine hospital in Kayseri (central Turkey) between December 2021 and January 2023, which coincided with the second half of COVID-19 pandemic. The study included 100 COVID-19 PCR-positive patients and 190 healthcare workers (HCWs). Antibody levels were followed up via quantitative anti-SARS-CoV-2 spike and qualitative anti-nucleocapsid immunoassays (Elecsys™). Antibody levels declined after infection but persisted for at least 6–8 months. Individuals who had received only CoronaVac had higher anti-nucleocapsid antibody levels in the early months than those who received mixed vaccination. However, anti-spike antibodies persisted longer and at higher levels in individuals who had received mixed vaccinations. This suggests that combining two different vaccine platforms may provide a synergistic effect, resulting in more durable and broad-spectrum immunity against SARS-CoV-2. The study provides information about the vaccination and antibody status of healthcare workers in the second half of the pandemic and provides valuable insights into the dynamics of antibody responses to COVID-19 infection and vaccination.
Open AccessCOVID-19 Antibody Levels among Various Vaccination Groups, One-Year Antibody Follow-Up in Two University Hospitals from Western and Central Turkey
Various clinical outcomes, reinfections, vaccination programs, and antibody responses resulted from the COVID-19 pandemic. This study investigated the time-dependent changes in SARS-CoV-2 antibody responses in infected and/or vaccinated and unvaccinated individuals and to provide insights into spike and nucleocapsid antibodies, which fluctuate during infectious and non-infectious states. This cohort study was carried out at the Ege University Faculty of Medicine hospital in İzmir (western Turkey) and the Erciyes University Faculty of Medicine hospital in Kayseri (central Turkey) between December 2021 and January 2023, which coincided with the second half of COVID-19 pandemic. The study included 100 COVID-19 PCR-positive patients and 190 healthcare workers (HCWs). Antibody levels were followed up via quantitative anti-SARS-CoV-2 spike and qualitative anti-nucleocapsid immunoassays (Elecsys™). Antibody levels declined after infection but persisted for at least 6–8 months. Individuals who had received only CoronaVac had higher anti-nucleocapsid antibody levels in the early months than those who received mixed vaccination. However, anti-spike antibodies persisted longer and at higher levels in individuals who had received mixed vaccinations. This suggests that combining two different vaccine platforms may provide a synergistic effect, resulting in more durable and broad-spectrum immunity against SARS-CoV-2. The study provides information about the vaccination and antibody status of healthcare workers in the second half of the pandemic and provides valuable insights into the dynamics of antibody responses to COVID-19 infection and vaccination.
- 12 June 2023
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 62 (2) , 234-239
Evaluation of a SARS-CoV-2 antigen test in the rapid diagnosis of COVID-19 suspected patients
Aim: Diagnostic testing for SARS-CoV-2 is an important component of the overall COVID-19 prevention and control strategy. Antigen detection using lateral flow assay (LFA) platforms can be performed at the point-of-care, providing quick results while being inexpensive and simple to perform. The current study sought to determine the success of a rapid antigen test in COVID-19 suspected cases, as well as the characteristics of discrepant results. Materials and Methods: Upper respiratory samples from 352 adult patients suspected of acute COVID-19 cases with related symptoms for 18 years old) suspected of acute COVID-19 cases. The patients ranged in age from 18 to 88 years old, with a median age of 41.25 years. A routine test for SARS-CoV-2 RNA found positive results in 127 (37.1%) of the patients and negative results in 225 (63.9%). The COVID-19 Ag test was positive in 116(33%) of these patients' nasal swab samples and negative in 236 (67%). The sensitivity and specificity of the COVID-19 Ag test was 89.7% and 99%, respectively. Conclusion: A rapid SARS-CoV-2 antigen test, which will be tested easily and supervised by medical personnel, could help decide for immediate isolation for patients or asymptomatic individuals that are shedding large number of viruses. In this study, lower viral loads can be strongly linked to the false negative antigen test results.
- 12 June 2023
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 62 (2) , 234-239
Evaluation of a SARS-CoV-2 antigen test in the rapid diagnosis of COVID-19 suspected patients
Aim: Diagnostic testing for SARS-CoV-2 is an important component of the overall COVID-19 prevention and control strategy. Antigen detection using lateral flow assay (LFA) platforms can be performed at the point-of-care, providing quick results while being inexpensive and simple to perform. The current study sought to determine the success of a rapid antigen test in COVID-19 suspected cases, as well as the characteristics of discrepant results. Materials and Methods: Upper respiratory samples from 352 adult patients suspected of acute COVID-19 cases with related symptoms for 18 years old) suspected of acute COVID-19 cases. The patients ranged in age from 18 to 88 years old, with a median age of 41.25 years. A routine test for SARS-CoV-2 RNA found positive results in 127 (37.1%) of the patients and negative results in 225 (63.9%). The COVID-19 Ag test was positive in 116(33%) of these patients' nasal swab samples and negative in 236 (67%). The sensitivity and specificity of the COVID-19 Ag test was 89.7% and 99%, respectively. Conclusion: A rapid SARS-CoV-2 antigen test, which will be tested easily and supervised by medical personnel, could help decide for immediate isolation for patients or asymptomatic individuals that are shedding large number of viruses. In this study, lower viral loads can be strongly linked to the false negative antigen test results.
- Open Access
- 26 April 2021
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (2) , 173-178
Reflections from Ege University Medical School’s clinical internship mentoring program (2011–2018)
Objectives: Ege University Medical School initiated system based integrated clinical internship in 2011. The need for a mentor who would closely monitor and guide the student in knowledge and skill gains for every clinical internship block and who would be an academic role model was well established. The aim of this study reports the results of the clinical internship mentoring program in the Ege University Medical School. Methods: The Clinical Internship Counseling Committee reviewed similar programs in the literature, conducted focus group discussions, determined the wishes and needs of the students, and developed a mentoring program. Results: The program was initiated by announcing the student-mentor matches and the procedure which was based on meetings of the student-mentor at the 1st, 8th and 13th weeks of the integrated internship. This meeting was designed to be a time for the mentor to guide the student to achieve the internship goals, to establish his/her internship progress file and to be an academic role model. At the final evaluation of the mentor, communication between student and the progress in the establishment of the internship progress file contributed to the 5% of the final internship success grade. Conclusions: Evaluation of 7 years of experience led to the agreement that the goals of clinical internship program should be integrated into the newly established “Student Mentorship Program” that starts at the 1st year of the medical school.
- 26 April 2021
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (2) , 173-178
Open AccessReflections from Ege University Medical School’s clinical internship mentoring program (2011–2018)
Objectives: Ege University Medical School initiated system based integrated clinical internship in 2011. The need for a mentor who would closely monitor and guide the student in knowledge and skill gains for every clinical internship block and who would be an academic role model was well established. The aim of this study reports the results of the clinical internship mentoring program in the Ege University Medical School. Methods: The Clinical Internship Counseling Committee reviewed similar programs in the literature, conducted focus group discussions, determined the wishes and needs of the students, and developed a mentoring program. Results: The program was initiated by announcing the student-mentor matches and the procedure which was based on meetings of the student-mentor at the 1st, 8th and 13th weeks of the integrated internship. This meeting was designed to be a time for the mentor to guide the student to achieve the internship goals, to establish his/her internship progress file and to be an academic role model. At the final evaluation of the mentor, communication between student and the progress in the establishment of the internship progress file contributed to the 5% of the final internship success grade. Conclusions: Evaluation of 7 years of experience led to the agreement that the goals of clinical internship program should be integrated into the newly established “Student Mentorship Program” that starts at the 1st year of the medical school.
- Open Access
- 1 January 2021
- Published by Kare Publishing in Hepatology Forum
- Vol. 2 (2) , 43-48
Significance of detectable hepatitis B virus DNA in liver allograft tissue in long-term follow-up of liver transplant recipients
Background and Aim: The objective of this study was to evaluate the long-term presence of hepatitis B virus (HBV) DNA in the liver grafts of liver transplant patients who received hepatitis B immunoglobulin (HBIg) plus oral antiviral hepatitis B virus prophylaxis and had negative HBV serum markers. Materials and Methods: Patients aged 18 years or older who underwent liver transplantation for HBV-related liver disease, had negative serum viral markers, and had a liver biopsy at least 3 years after liver transplantation were eligible for this study. Clinical, serological, and pathological data were retrospectively obtained from medical records. The HBV DNA of liver biopsy specimens was assessed using the polymerase chain reaction technique. Results: A total of 150 patients were included. A positive HBV DNA result was seen in 18 (12%) of the liver biopsies. The presence of intrahepatic HBV DNA was not associated with pre-transplantation serum viral markers, type of pre- or post-transplantation antiviral treatment, or post-transplantation immunosuppressive treatment. Conclusion: The findings suggest that while treatment with HBIg plus oral antiviral as post-transplantation HBV prophylaxis may result in a percentage of patients with persistent HBV DNA in the graft, the presence of HBV DNA in the liver graft may not be related to clinical HBV recurrence.
- 1 January 2021
- Published by Kare Publishing in Hepatology Forum
- Vol. 2 (2) , 43-48
Open AccessSignificance of detectable hepatitis B virus DNA in liver allograft tissue in long-term follow-up of liver transplant recipients
Background and Aim: The objective of this study was to evaluate the long-term presence of hepatitis B virus (HBV) DNA in the liver grafts of liver transplant patients who received hepatitis B immunoglobulin (HBIg) plus oral antiviral hepatitis B virus prophylaxis and had negative HBV serum markers. Materials and Methods: Patients aged 18 years or older who underwent liver transplantation for HBV-related liver disease, had negative serum viral markers, and had a liver biopsy at least 3 years after liver transplantation were eligible for this study. Clinical, serological, and pathological data were retrospectively obtained from medical records. The HBV DNA of liver biopsy specimens was assessed using the polymerase chain reaction technique. Results: A total of 150 patients were included. A positive HBV DNA result was seen in 18 (12%) of the liver biopsies. The presence of intrahepatic HBV DNA was not associated with pre-transplantation serum viral markers, type of pre- or post-transplantation antiviral treatment, or post-transplantation immunosuppressive treatment. Conclusion: The findings suggest that while treatment with HBIg plus oral antiviral as post-transplantation HBV prophylaxis may result in a percentage of patients with persistent HBV DNA in the graft, the presence of HBV DNA in the liver graft may not be related to clinical HBV recurrence.
- Open Access
- 1 January 2021
- Published by Kare Publishing in Northern Clinics of Istanbul
- Vol. 8 (6) , 568-574
Predictive value of FibroScan in detecting liver fibrosis in HBeAg negative patients with chronic hepatitis B whose HBV DNA 2000-20000 IU/ml with ALT 1-2 times the upper limit of normal and those with HBV DNA >20000 IU/ml and normal ALT
OBJECTIVE: In hepatitis B infection, it is difficult to make a treatment decision in patients with slightly elevated transaminases and HBV DNA level between 2000 and 20000 IU/ml, and in those with normal ALT, despite high levels of HBV DNA. Objectives: In HBeAg negative patients whose HBV DNA levels were between 2000 and 20000 IU/ml with ALT 1-2 times the upper limit of normal (ULN) and those with HBV DNA >20000 IU/ml and normal ALT, the concordance between liver fibrosis in biopsy and liver stiffness measured by transient elastography with FibroScan (R) (FS) was investigated, and diagnostic value of FS to predict the liver fibrosis was tested. METHODS: The patients were selected from the outpatient hepatology clinics between the dates of November 2014 and October 2016 among those who were taken liver biopsy. Transient elastography was obtained within 3 months after liver biopsy. The diagnostic value of FS in detecting advanced fibrosis or moderate to advanced (MTA) fibrosis was investigated for each group. RESULTS: In 38 patients with HBV DNA 2000-20000 IU/ml and ALT 1-2xULN, advanced fibrosis was detected in only one patient (2.6%) on liver biopsy, sensitivity of FS to show advanced fibrosis is 100%, specificity 78.3%, and diagnostic accuracy rate 79%. The area under curve was determined to be 0.892. In detecting MTA fibrosis, these values are 100%, 62%, 71%, and 0.810, respectively. Of 79 patients with HBV DNA >20000 IU/ml and normal ALT, five had advanced (5.5%) and 18 had MTA (23%) fibrosis. Sensitivity of FS in detecting advanced fibrosis was 100%, specificity 87.8%, and accuracy 88.6%, and these values for MTA fibrosis were 85.7%, 81%, and 82.3%, respectively. CONCLUSION: Because of false negativity in a few patients with HBV DNA >20000 IU/ml in detecting MTA, FS may be combined with other non-invasive techniques. Negative predictive values of FS in predicting advanced or MTA fibrosis were very high, while positive predictive values were low. However, FS may save several patients from liver biopsy.
- 1 January 2021
- Published by Kare Publishing in Northern Clinics of Istanbul
- Vol. 8 (6) , 568-574
Open AccessPredictive value of FibroScan in detecting liver fibrosis in HBeAg negative patients with chronic hepatitis B whose HBV DNA 2000-20000 IU/ml with ALT 1-2 times the upper limit of normal and those with HBV DNA >20000 IU/ml and normal ALT
OBJECTIVE: In hepatitis B infection, it is difficult to make a treatment decision in patients with slightly elevated transaminases and HBV DNA level between 2000 and 20000 IU/ml, and in those with normal ALT, despite high levels of HBV DNA. Objectives: In HBeAg negative patients whose HBV DNA levels were between 2000 and 20000 IU/ml with ALT 1-2 times the upper limit of normal (ULN) and those with HBV DNA >20000 IU/ml and normal ALT, the concordance between liver fibrosis in biopsy and liver stiffness measured by transient elastography with FibroScan (R) (FS) was investigated, and diagnostic value of FS to predict the liver fibrosis was tested. METHODS: The patients were selected from the outpatient hepatology clinics between the dates of November 2014 and October 2016 among those who were taken liver biopsy. Transient elastography was obtained within 3 months after liver biopsy. The diagnostic value of FS in detecting advanced fibrosis or moderate to advanced (MTA) fibrosis was investigated for each group. RESULTS: In 38 patients with HBV DNA 2000-20000 IU/ml and ALT 1-2xULN, advanced fibrosis was detected in only one patient (2.6%) on liver biopsy, sensitivity of FS to show advanced fibrosis is 100%, specificity 78.3%, and diagnostic accuracy rate 79%. The area under curve was determined to be 0.892. In detecting MTA fibrosis, these values are 100%, 62%, 71%, and 0.810, respectively. Of 79 patients with HBV DNA >20000 IU/ml and normal ALT, five had advanced (5.5%) and 18 had MTA (23%) fibrosis. Sensitivity of FS in detecting advanced fibrosis was 100%, specificity 87.8%, and accuracy 88.6%, and these values for MTA fibrosis were 85.7%, 81%, and 82.3%, respectively. CONCLUSION: Because of false negativity in a few patients with HBV DNA >20000 IU/ml in detecting MTA, FS may be combined with other non-invasive techniques. Negative predictive values of FS in predicting advanced or MTA fibrosis were very high, while positive predictive values were low. However, FS may save several patients from liver biopsy.